Alnylam Pharmaceuticals, Inc. (0HD2.L)

USD 255.29

(-2.5%)

Long Term Debt Summary of Alnylam Pharmaceuticals, Inc.

  • Alnylam Pharmaceuticals, Inc.'s latest annual long term debt in 2023 was 2.34 Billion USD , up 3.26% from previous year.
  • Alnylam Pharmaceuticals, Inc.'s latest quarterly long term debt in 2024 Q2 was 2.36 Billion USD , up 0.28% from previous quarter.
  • Alnylam Pharmaceuticals, Inc. reported annual long term debt of 2.26 Billion USD in 2022, up 24.21% from previous year.
  • Alnylam Pharmaceuticals, Inc. reported annual long term debt of 1.82 Billion USD in 2021, up 46.2% from previous year.
  • Alnylam Pharmaceuticals, Inc. reported quarterly long term debt of 2.35 Billion USD for 2024 Q3, down -0.33% from previous quarter.
  • Alnylam Pharmaceuticals, Inc. reported quarterly long term debt of 2.36 Billion USD for 2024 Q2, up 0.28% from previous quarter.

Annual Long Term Debt Chart of Alnylam Pharmaceuticals, Inc. (2023 - 2012)

Historical Annual Long Term Debt of Alnylam Pharmaceuticals, Inc. (2023 - 2012)

Year Long Term Debt Long Term Debt Growth
2023 2.34 Billion USD 3.26%
2022 2.26 Billion USD 24.21%
2021 1.82 Billion USD 46.2%
2020 1.24 Billion USD 352.5%
2019 276.13 Million USD 820.45%
2018 30 Million USD 0.0%
2017 30 Million USD -80.0%
2016 150 Million USD 0.0%
2015 - USD 0.0%
2014 - USD 0.0%
2013 - USD 0.0%
2012 - USD 0.0%

Peer Long Term Debt Comparison of Alnylam Pharmaceuticals, Inc.

Name Long Term Debt Long Term Debt Difference
uniQure N.V. 130.06 Million USD -1701.425%
Agios Pharmaceuticals, Inc. 56.98 Million USD -4011.434%
Amicus Therapeutics, Inc. 387.85 Million USD -504.093%
Atara Biotherapeutics, Inc. 45.69 Million USD -5027.753%
bluebird bio, Inc. 224.41 Million USD -944.04%
Cara Therapeutics, Inc. 37.07 Million USD -6219.005%
Imunon, Inc. 1.13 Million USD -205555.964%
Editas Medicine, Inc. 24.37 Million USD -9513.589%
IQVIA Holdings Inc. 12.95 Billion USD 81.914%
Mettler-Toledo International Inc. 1.97 Billion USD -18.601%
Myriad Genetics, Inc. 130.9 Million USD -1689.934%
Neurocrine Biosciences, Inc. 258.3 Million USD -807.094%
Supernus Pharmaceuticals, Inc. 33.19 Million USD -6958.152%
Verastem, Inc. 40.08 Million USD -5744.993%
Walgreens Boots Alliance, Inc. 8.04 Billion USD 70.872%
Waters Corporation 2.3 Billion USD -1.627%
Thermo Fisher Scientific Inc. 31.3 Billion USD 92.516%
Biogen Inc. 7.18 Billion USD 67.405%
Nektar Therapeutics 112.62 Million USD -1980.376%
Perrigo Company plc 3.63 Billion USD 35.504%
Dynavax Technologies Corporation 252.41 Million USD -828.232%
Illumina, Inc. 1.48 Billion USD -57.356%
Corbus Pharmaceuticals Holdings, Inc. 3.23 Million USD -72246.124%
Iovance Biotherapeutics, Inc. 1 Million USD -234202.4%
Heron Therapeutics, Inc. 173.75 Million USD -1248.48%
Unity Biotechnology, Inc. 23.53 Million USD -9853.796%
BioMarin Pharmaceutical Inc. 593.09 Million USD -295.05%
Sangamo Therapeutics, Inc. 33.51 Million USD -6890.971%
Evolus, Inc. 120.35 Million USD -1846.696%
Adicet Bio, Inc. 17.7 Million USD -13135.18%
Aclaris Therapeutics, Inc. 3.07 Million USD -76120.69%
Regeneron Pharmaceuticals, Inc. 2.7 Billion USD 13.314%
Esperion Therapeutics, Inc. 501.54 Million USD -367.16%
FibroGen, Inc. 89.69 Million USD -2512.154%
Agilent Technologies, Inc. 2.73 Billion USD 14.332%
OPKO Health, Inc. 222.03 Million USD -955.255%
Homology Medicines, Inc. 43.17 Million USD -5326.681%
Geron Corporation 35.05 Million USD -6584.614%
Exelixis, Inc. 189.94 Million USD -1133.534%
Viking Therapeutics, Inc. 936 Thousand USD -250223.077%
Anavex Life Sciences Corp. - USD -Infinity%
Intellia Therapeutics, Inc. 96.74 Million USD -2321.805%
Zoetis Inc. 6.56 Billion USD 64.305%
Axsome Therapeutics, Inc. 178.07 Million USD -1215.788%
Abeona Therapeutics Inc. 4.4 Million USD -53126.352%
Vertex Pharmaceuticals Incorporated 724.7 Million USD -223.31%
Kala Pharmaceuticals, Inc. 34.19 Million USD -6752.951%
Ionis Pharmaceuticals, Inc. 1.4 Billion USD -67.314%
Sarepta Therapeutics, Inc. 1.13 Billion USD -106.887%
Corcept Therapeutics Incorporated - USD -Infinity%
Halozyme Therapeutics, Inc. 1.49 Billion USD -56.28%
Blueprint Medicines Corporation 610.96 Million USD -283.498%
Insmed Incorporated 1.19 Billion USD -96.34%
TG Therapeutics, Inc. 100.11 Million USD -2240.262%
Incyte Corporation 29.16 Million USD -7934.511%
Emergent BioSolutions Inc. 446.5 Million USD -424.753%